Andrea Boutros: AMPLIFY-201 Vaccine Boosts T-Cell Responses in KRAS+ PDAC/CRC
Andrea Boutros, Medical Doctor and Oncology Resident at San Martino Polyclinic Hospital, shared a post on X about a paper by Zev A. Wainberg et al. published in Nature Medicine:
“Lymph-node–targeted amphiphile vaccine (AMPLIFY-201) in MRD+ mKRAS PDAC/CRC: robust mKRAS-specific T-cell responses and immune ‘spreading’.
A step toward post-surgery MRD interception?
- Amphiphile = hydrophilic + lipophilic tail; it sticks to albumin in blood/lymph.
- Albumin acts as a shuttle to lymph nodes, where APCs present antigen – stronger CD8+/CD4+ responses.
Higher vaccine-induced T-cell responses – longer RFS/OS. Signals are encouraging; durability with boosters noted.
Mechanism-driven immunotherapy in driver-mutant solid tumors.
Small, non-randomized, MRD-positive cohort – needs randomized confirmation and standardized MRD assays.
How would you design the phase 2/3? Eligibility, endpoints, MRD thresholds?”
Title: Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Authors: Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant, Eileen M. O’Reilly
You can read the Full Article in Nature Medicine.
More posts featuring Andrea Boutros.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023